pubs.acs.org/joc
recently a three-step procedure featuring regioselective alky-
Aza-1,2,3-triazole-3-alanine Synthesis via
Copper-Catalyzed 1,3-Dipolar Cycloaddition on
Aza-progargylglycine
lation and chemoselective deprotection of an azaglycine
semicarbazone to afford a variety of azapeptides directly
on solid support.5 With the idea that multiple combinatorial
libraries of azapeptides could be obtained via the making of
“libraries from libraries”,6 we have incorporated aza-pro-
pargylglycine moieties within a peptide to introduce a new
series of aza-1,2,3-triazole-3-alanine residues (Figure 1).
Growth Hormone Releasing Peptide-6 (His-D-Trp-Ala-
Trp-D-Phe-Lys-NH2, GHRP-6), a synthetic hexapeptide that
binds to two distinct receptors,7 was chosen as the target pep-
tide to develop this methodology. Incorporation of aza-Phe
for Trp4 conferred selectivity for the CD36 receptor,5 a target
for the development of treatments of angiogenesis-related
diseases. A combinatorial approach to incorporate novel hete-
roaryl alanine residues at the 4-position was deemed desirable
for improving binding affinity of the lead [AzaPhe4]GHRP-6
azapeptide.
Caroline Proulx and William D. Lubell*
Deꢀpartement de Chimie, Universiteꢀ de Montreꢀal, C.P. 6128,
ꢀ ꢀ
Succursale Centre-Ville, Montreal, Quebec H3C 3J7, Canada
Received May 17, 2010
The Cu-catalyzed azide-alkyne [3þ2] cycloaddition has
proven effective for making triazole peptidomimetics.8 Pro-
pargyl glycine, propargyl amides, and N-propargyl glycine
peptoids all have served as substrates for triazole formation
leading to macrocyclization,9,10 carbohydrate ligation,11
peptoid oligomer functionalization,12 as well as amide bond
and histidine isostere synthesis.8a,13 Precluding the solution-
phase synthesis of azido acids and propargyl glycine resi-
dues, and taking advantage of the propensity for aza-amino
acids to adopt β-turns, we describe now the solid-phase
synthesis of aza-1,2,3-triazole-3-alanine-containing azapep-
tides using aza-propargyl glycine residues anchored on Rink
amide resin.
The parallel synthesis of seven aza-1,2,3-triazole-3-ala-
nine azapeptides of the Growth Hormone Releasing
Peptide-6 (GHRP-6) was accomplished via a Cu-cata-
lyzed azide-alkyne [3þ2] cycloaddition on an aza-pro-
pargylglycine residue anchored on Rink amide resin.
Circular dichroism spectroscopy in water demonstrated
that azapeptides which possess an aza-1,2,3-triazole-3-
alanine residue at the Trp4 position of the GHRP-6
sequence adopt β-turn conformations.
[Aza-1,2,3-triazole-3-alanine4]GHRP-6 analogues were
synthesized by elaboration of the submonomer methodology
for aza-propargylglycine synthesis by using propargyl bro-
mide as electrophile5 to alkylate a semicarbazone residue on
solid phase. Subsequent 1,3-dipolar cycloaddition was ac-
complished with aryl iodides, sodium azide, and copper iodide
in a tandem aryl azide formation/cycloaddition reaction cas-
cade (Table 1, Figure 2).14 Seven triazoles were synthesized in
Azapeptides are peptidomimetics in which the R carbon of
one or more amino acids has been replaced with a nitrogen
atom.1 The longstanding interest in aza-amino acids as
peptide mimics stems from their increased stability,2 resist-
ance to proteases,3 and ability to induce conformational
rigidity, favoring the formation of β turns.4 Until recently,
the incorporation of side-chain diversity onto the aza-amino
acid residue was limited by the solution-phase synthesis of
protected N-alkyl hydrazine building blocks prior to their
activation and incorporation onto a growing peptide chain.
Toward the combinatorial synthesis of azapeptides, we described
(5) Sabatino, D.; Proulx, C.; Klocek, S.; Bourguet, C. B.; Boeglin, D.;
Ong, H.; Lubell, W. D. Org. Lett. 2009, 11, 3650.
€
(6) Houghten, R. A.; Blondelle, S. E.; Dooley, C. T.; Dorner, B.; Eichler,
J.; Ostresh, J. M. Mol. Diversity 1996, 2, 41.
(7) Demers, A.; McNicoll, N.; Febbraio, M.; Servant, M.; Marleau, S.;
Silverstein, R.; Ong, H. Biochem. J. 2004, 417.
(8) (a) Tornoe, C. W.; Christensen, C.; Meldal, M. J. Org. Chem. 2002, 67,
3057–3064. (b) Rostovtsev, V. V.; Green, L. G.; Fokin, V. V.; Sharpless,
K. B. Angew. Chem., Int. Ed. 2002, 41, 2596.
(9) Selected examples include: (a) Bock, V. D.; Speijer, D.; Hiemstra, H.;
van Maarseveen, J. H. Org. Biomol. Chem. 2007, 5, 971. (b) Turner, R. A.;
Oliver, A. G.; Lokey, R. S. Org. Lett. 2007, 9, 5011.
(1) Gante, J. Synthesis 1989, 405.
(10) Selected examples include: (a) Holub, J. M.; Jang, H.; Kirshenbaum,
K. Org. Lett. 2007, 9, 3275. (b) Jagasia, R.; Holub, J. M.; Bollinger, M.;
Kirshenbaum, K.; Finn, M. G. J. Org. Chem. 2009, 74, 2964.
(11) (a) Kuijpers, B. H. M.; Groothuys, S.; Keereweer, A. R.; Quaedflieg,
P. J. L. M.; Blaauw, R. H.; van Delft, F. L.; Rutjes, F. P. J. T. Org. Lett. 2004,
6, 3123. (b) Lee, D. J.; Mandal, K.; Harris, P. W. R.; Brimble, M. A.; Kent,
S. B. H. Org. Lett. 2009, 11, 5270.
(2) (a) Gassman, J. M. Bioorg. Med. Chem. Lett. 1996, 6, 1771. (b) Wipf,
P.; Adeyeye, C. M.; Rusnak, J. M.; Lazo, J. S. Bioorg. Med. Chem. 1996, 4,
1585.
(3) Dugave, C.; Demange, L. Lett. Pept. Sci. 2003, 10, 1.
(4) (a) Reynolds, C. H.; Hormann, R. E. J. Am. Chem. Soc. 1996, 118,
9395–9401. (b) Lee, H.-J.; Song, J.-W.; Choi, Y.-S.; Park, H.-M.; Lee, K.-B.
ꢀ
J. Am. Chem. Soc. 2002, 124, 11881–11893. (c) Andre, F.; Boussard, G.;
Bayeul, D.; Didierjean, C.; Aubry, A.; Marraud, M. J. Pept. Res. 1997, 49,
(12) Holub, J. M.; Jang, H.; Kirshenbaum, K. Org. Biomol. Chem. 2006,
4, 1497.
ꢀ
556–562. (d) Andre, F.; Vicherat, A.; Boussard, G.; Aubry, A.; Marraud, M.
J. Peptide Res. 1997, 50, 372–381.
(13) Gajewski, M.; Seaver, B.; Esslinger, C. S. Bioorg. Med. Chem. Lett.
2007, 17, 4163–4166.
DOI: 10.1021/jo100957z
r
Published on Web 06/28/2010
J. Org. Chem. 2010, 75, 5385–5387 5385
2010 American Chemical Society